Cargando…

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

AIM: To evaluate the efficacy and safety of ipragliflozin vs placebo as add‐on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus (T2DM). METHODS: This double‐blind, placebo‐controlled, multi‐centre, phase III study was conducted in Korea in 2015 to 2017. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Kyung‐Ah, Chon, Suk, Chung, Choon Hee, Lim, Soo, Lee, Kwan‐Woo, Baik, SeiHyun, Jung, Chang Hee, Kim, Dong‐Sun, Park, Kyong Soo, Yoon, Kun‐Ho, Lee, In‐Kyu, Cha, Bong‐Soo, Sakatani, Taishi, Park, Sumi, Lee, Moon‐Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175352/ https://www.ncbi.nlm.nih.gov/pubmed/29862619 http://dx.doi.org/10.1111/dom.13394

Ejemplares similares

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
por: Seino, Yutaka, et al.
Publicado: (2021)

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
por: Ishihara, Hisamitsu, et al.
Publicado: (2018)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020)

Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study
por: Lee, Mi Young, et al.
Publicado: (2014)

Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo‐controlled, double‐blind, multicenter trial
por: Lu, Chieh‐Hsiang, et al.
Publicado: (2015)

Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
por: Hong, Sang‐Mo, et al.
Publicado: (2017)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial
por: Kim, Yonghyun, et al.
Publicado: (2018)

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
por: Min, Kyung-Wan, et al.
Publicado: (2017)

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
por: Han, Eugene, et al.
Publicado: (2020)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus
por: Chung, Hye Soo, et al.
Publicado: (2011)

Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
por: Yang, Hae Kyung, et al.
Publicado: (2019)

Efficacy of ipragliflozin as monotherapy or as add‐on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics
por: Osonoi, Takeshi, et al.
Publicado: (2017)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
por: Li, Chun-Jun, et al.
Publicado: (2014)

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent
por: Tang, Yun-Zhao, et al.
Publicado: (2015)

Colon Transit Time May Predict Inadequate Bowel Preparation in Patients With Chronic Constipation
por: Park, Hong Jun, et al.
Publicado: (2015)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
por: Ku, Eu Jeong, et al.
Publicado: (2015)

A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise
por: Jung, Chang Hee, et al.
Publicado: (2015)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin
por: Chung, Hye Soo, et al.
Publicado: (2014)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME‐V study)
por: Koshizaka, Masaya, et al.
Publicado: (2020)

Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
por: Sharma, Manuj, et al.
Publicado: (2017)

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
por: Kim, Hye-soon, et al.
Publicado: (2014)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2017)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
por: Oh, Tae Jung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vqktiqek6fdfqm97ori84ilti5